Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01484626 · ClinicalTrials.gov registry record · Phase 1
Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma
A Phase 1 study, sponsored by Loyola University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01484626 is a Phase 1 study that was terminated before completion, run by Loyola University. The registered enrollment target is 3 participants.
The verdict
NCT01484626, a Phase 1 study, was terminated before completion, sponsored by Loyola University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety and efficacy of the use of bendamustine in combination with a commonly used combination chemotherapy to treat relapsed and refractory multiple myeloma. The study will be conducted in two phases. Participants in phase I will receive 1 of 4 escalating doses of bendamustine. Once the maximum tolerated dose of bendamustine is determined, phase II of this trial will begin. Participants in phase II will receive the maximum tolerated dose of bendamustine in combination with standard of care chemotherapy.
Interventions
- DRUG Bendamustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-05-05 |
| Est. Completion | 2014-06-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01484626
The ClinicalTrials.gov registry entry for NCT01484626 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loyola University, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bendamustine is the first listed.
NCT01484626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01484626 about?
NCT01484626 is a clinical study titled "Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma". The purpose of the study is to determine the safety and efficacy of the use of bendamustine in combination with a commonly used combination chemotherapy to treat relapsed and refractory multiple myeloma. The study will be conducted in two phases. Participants in phase I will receive 1 of 4 escalatin...
What is the current status of trial NCT01484626?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2011-05-05. Estimated completion is 2014-06-18.
What interventions are being tested in trial NCT01484626?
The interventions under investigation include: Bendamustine (DRUG).
Who is sponsoring clinical trial NCT01484626?
This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.